Skip to main content

Investor Relations

IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Our approach integrates capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patient populations most likely to benefit from our targeted therapies.

 

Corporate Presentation IDEAYA Highlights Investor Alerts

 
Recent News
Dec 5, 2023
IDEAYA Biosciences to Participate in Upcoming December 2023 Investor Relations Event

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor...

Dec 4, 2023
IDEAYA Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Trodelvy® and IDE397 Combination in MTAP-Deletion Bladder Cancer

Entered into Clinical Study Collaboration and Supply Agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with sacituzumab-govitecan-hziy ("Trodelvy") Gilead's Trop-2...

Dec 3, 2023
IDEAYA Announces Agenda for Investor R&D Day Webcast on December 4, 2023

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced agenda topics for its Investor R&D...

All Releases

Stock Info
NASDAQIDYA

Stock Information

Events
IDEAYA Biosciences Investor R&D Day
Monday, December 4, 2023
8:00am EST
Jefferies London Healthcare Conference
Tuesday, November 14, 2023
3:00am EST

Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Maury Raycroft, Ph.D. Equity Research Analyst, Biotechnology

All Events

WE ARE DEDICATED TO

Improving Lives Through Transformative Precision Medicines

INVESTOR INSIGHTS

Close Menu